A study shows that MET overexpression/overactivation leads to NSCLC resistance to dual EGFR/Her2 inhibitors due to physical interaction of Met with EGFR and Her2 in NSCLC [86]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.